We are live on ! Find out more
PHVS icon

Pharvaris
PHVS

60 hedge funds and large institutions have $793M invested in Pharvaris in 2025 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 19 increasing their positions, 16 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

800% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 1

19% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 16

15% more funds holding

Funds holding: 52 → 60 (+8)

12% more capital invested

Capital invested by funds: $706M → $793M (+$87.2M)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

0.55% less ownership

Funds ownership: 83.21% → 82.66% (-0.55%)

Holders
60
Holders Change
+8
Holders Change %
+15.38%
% of All Funds
0.79%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
9
Increased
19
Reduced
16
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PBA
Paradigm Biocapital Advisors
New York
+$17.1M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$2.92M
3
TAM
TFG Asset Management
Cayman Islands
+$984K
4
ACM
ADAR1 Capital Management
Texas
+$550K
5
Citadel Advisors
Citadel Advisors
Florida
+$471K

Top Sellers

Rank Fund Capital Flow
1
VA
VR Adviser
New York
-$17.2M
2
OCA
Octagon Capital Advisors
New York
-$1.57M
3
SCM
Soleus Capital Management
Connecticut
-$1.32M
4
SFM
Sphera Funds Management
Israel
-$1.19M
5
Morgan Stanley
Morgan Stanley
New York
-$251K
Name Holding Trade Value Shares
Change 		Change in
Stake
GA
1
General Atlantic
New York
$133M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$95.4M +$435K +27,023 +0.5%
FCMI
3
Foresite Capital Management IV
California
$77.6M – – –
VP
4
venBio Partners
California
$75.5M – – –
Viking Global Investors
5
Viking Global Investors
Connecticut
$64.3M – – –
BCLSI
6
Bain Capital Life Sciences Investors
Massachusetts
$58.1M – – –
VA
7
VR Adviser
New York
$36M -$17.2M -1,065,100 -34%
DM
8
Deerfield Management
New York
$35.5M – – –
CC
9
Commodore Capital
New York
$33.6M – – –
NHAS
10
Novo Holdings A/S
Denmark
$30.4M – – –
CAM
11
Cormorant Asset Management
Massachusetts
$25.6M -$190K -11,800 -0.8%
PBA
12
Paradigm Biocapital Advisors
New York
$18.7M +$17.1M +1,062,911 New
5VM
13
5AM Venture Management
California
$14M – – –
T. Rowe Price Associates
14
T. Rowe Price Associates
Maryland
$13.5M +$2.92M +181,228 +31%
SCM
15
Soleus Capital Management
Connecticut
$12.9M -$1.32M -81,684 -10%
OCA
16
Octagon Capital Advisors
New York
$11.8M -$1.57M -97,220 -13%
RSCM
17
Rock Springs Capital Management
Maryland
$11M – – –
SI
18
Sofinnova Investments
California
$10.3M -$127K -7,871 -1%
SFM
19
Sphera Funds Management
Israel
$5.45M -$1.19M -73,925 -19%
PSC
20
Patient Square Capital
California
$4.3M -$19.5K -1,213 -0.5%
RA
21
Rosalind Advisors
Ontario, Canada
$3.94M – – –
BlackRock
22
BlackRock
New York
$3.54M +$133K +8,224 +4%
TAM
23
TFG Asset Management
Cayman Islands
$3.31M +$984K +61,105 +48%
TD Asset Management
24
TD Asset Management
Ontario, Canada
$1.75M +$345K +21,388 +27%
Northern Trust
25
Northern Trust
Illinois
$1.68M +$135K +8,393 +10%
1
2 3

PHVS Hedge Fund Activity: Q2 2025 in Review

60 of the 7,598 institutional investors tracked by Wall St. Rank reported a position in Pharvaris (PHVS) for Q2 2025, worth a combined $793M — up 12% from $706M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new PHVS positions and 1 closed out — a net gain of 8 holders — while 19 added to existing stakes and 16 trimmed.

The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $17.1M. The largest seller was VR Adviser, cutting an estimated $17.2M.

  • 60 institutional investors held Pharvaris (PHVS) as of Q2 2025, up from 52 in Q1 2025.
  • Funds reported $793M of Pharvaris stock for Q2 2025, up 12% quarter-over-quarter.
  • 9 funds opened new Pharvaris positions in Q2 2025 and 1 closed out, a net change of +8 holders.
  • The largest Pharvaris buyer in Q2 2025 was Paradigm Biocapital Advisors, an estimated $17.1M added.
  • The largest Pharvaris seller in Q2 2025 was VR Adviser, an estimated $17.2M sold.

Based on aggregated 13F filings for Q2 2025.